InflaRx N.V.

DB:IF0 Stock Report

Market Cap: €133.9m

InflaRx Valuation

Is IF0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IF0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IF0 (€1.84) is trading below our estimate of fair value (€127.66)

Significantly Below Fair Value: IF0 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IF0?

Key metric: As IF0 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for IF0. This is calculated by dividing IF0's market cap by their current book value.
What is IF0's PB Ratio?
PB Ratio2.1x
Book€65.28m
Market Cap€133.93m

Price to Book Ratio vs Peers

How does IF0's PB Ratio compare to its peers?

The above table shows the PB ratio for IF0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
2INV 2invest
1xn/a€62.7m
HPHA Heidelberg Pharma
3x-33.0%€105.8m
FYB Formycon
1.5x31.5%€857.2m
BIO3 Biotest
2x29.3%€1.3b
IF0 InflaRx
2.1x35.3%€141.3m

Price-To-Book vs Peers: IF0 is expensive based on its Price-To-Book Ratio (2.1x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does IF0's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
IF0 2.1xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: IF0 is good value based on its Price-To-Book Ratio (2.1x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is IF0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IF0 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IF0's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IF0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.84
€7.74
+321.4%
35.2%€12.12€4.74n/a4
Nov ’25€1.38
€7.06
+412.0%
28.0%€10.07€4.58n/a4
Oct ’25€1.32
€7.06
+434.1%
28.0%€10.07€4.58n/a4
Sep ’25€1.38
€7.09
+415.9%
27.9%€10.07€4.58n/a4
Aug ’25€1.38
€7.43
+439.1%
32.1%€11.17€4.60n/a4
Jul ’25€1.48
€7.43
+402.3%
32.1%€11.17€4.60n/a4
Jun ’25€1.24
€7.44
+498.5%
31.9%€11.17€4.65n/a4
May ’25€1.20
€7.38
+514.6%
31.8%€11.05€4.61n/a4
Apr ’25€1.35
€7.38
+448.4%
31.8%€11.05€4.61n/a4
Mar ’25€1.70
€9.15
+438.4%
57.1%€18.03€4.56n/a4
Feb ’25€1.53
€9.15
+499.8%
57.1%€18.03€4.56n/a4
Jan ’25€1.60
€9.45
+491.2%
54.2%€18.03€4.74n/a4
Dec ’24€1.22
€9.45
+674.4%
54.2%€18.03€4.74n/a4
Nov ’24€1.51
€9.45
+527.5%
54.1%€18.03€4.74€1.384
Oct ’24€2.61
€9.85
+278.0%
55.0%€19.06€5.58€1.324
Sep ’24€3.56
€9.78
+174.8%
55.7%€19.06€5.49€1.384
Aug ’24€3.64
€10.54
+189.5%
47.8%€19.23€7.33€1.384
Jul ’24€4.07
€10.54
+159.2%
47.8%€19.23€7.33€1.484
Jun ’24€3.87
€8.80
+127.8%
64.6%€19.23€1.84€1.245
May ’24€4.16
€9.88
+137.8%
70.7%€22.89€1.83€1.205
Apr ’24€1.71
€4.62
+170.6%
44.9%€7.41€1.84€1.354
Mar ’24€1.83
€4.84
+164.9%
46.1%€7.96€1.97€1.704
Feb ’24€2.08
€4.86
+133.5%
45.8%€7.96€1.97€1.534
Jan ’24€2.66
€5.33
+100.6%
47.2%€7.96€1.97€1.604
Dec ’23€2.48
€5.41
+118.3%
47.8%€7.96€1.97€1.224
Nov ’23€2.62
€5.28
+101.7%
45.9%€8.19€1.96€1.514

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.65

7D

-3.7%

1Y

76.2%

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.60

7D

5.7%

1Y

27.6%

Pharming Group

€491.5m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.70

7D

-0.7%

1Y

-34.1%